[Treatment of oedematous, proliferative and neovascular diseases by intravitreal triamcinolone acetonide].
BACKGROUND
Recent studies have suggested that intravitreal triamcinolone acetonide may be a therapeutical possibility for treating of various intraocular neovascular, oedematous and proliferative diseases.


RESULTS
Gain in visual acuity was relatively highest for eyes with intraretinal oedematous diseases such as diffuse diabetic macular oedema and various types of cystoid macular oedema due to reasons such as retinal venous occlusions and uveitis. Intravitreal triamcinolone may be useful as angiostatic therapy in eyes with iris neovascularisation and proliferative ischaemic retinopathies. Possibly, intravitreal triamcinolone may be helpful for exudative age-related macular degeneration. In eyes with chronic therapy resistant ocular hypotony, intravitreal triamcinolone can induce an increase in intraocular pressure. The role of intravitreal triamcinolone as adjunctive treatment of proliferative vitreoretinopathy has not been determined so far. Complications of intravitreal triamcinolone include secondary ocular hypertension in about 50 % of the eyes injected, with one per cent of the eyes necessitating antiglaucomatous filtrating surgery; a cataractogenic effect; and postoperative infectious endophthalmitis. Long-term studies of more than 3 years follow-up have been missing so far, so that there is no reliable information on long-term complications. The injection can be combined with cataract surgery. Cataract surgery performed some months after the injection did not show a markedly elevated rate of complications. If vision increases after the intravitreal triamcinolone injection, the injection can be repeated. The duration of the effect of a single intravitreal injection of triamcinolone ranges between 2 and 9 months. Triamcinolone acetonide was detected in the aqueous humour nine months after an intravitreal injection of 25 mg.


CONCLUSIONS
Intravitreal triamcinolone acetonide may offer a possibility for adjunctive treatment of intraocular oedematous, neovascular and proliferative diseases.
Jonas
Jost B
JB
Universitäts-Augenklinik, Fakultät für Klinische Medizin Mannheim der Ruprecht-Karls-Universität Heidelberg. Jost.Jonas@augen.ma.uni-heidelberg.de
Kreissig
Ingrid
I
Degenring
Robert F
RF
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy* / Q000209:etiology; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects; D018630:Vitreoretinopathy, Proliferative / Q000188:drug therapy* / Q000209:etiology; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D014222:Triamcinolone Acetonide